Inhibitors of poly (ADP-ribose) polymerase (PARP) have been approved for patients with pancreatic cancer (including PACC) harboring germline BRCA1 or BRCA2 pathogenic mutations, and further studies are investigating the benefit of PARP inhibitors in pancreatic cancers with HR deficiency (HRD) due to alterations affecting other canonical HR-related genes (NCT04858334), and in unselected PACC (NCT05286827). This evidence concerns the gene BRCA2 and pancreatic neoplasm.